Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00642148




Registration number
NCT00642148
Ethics application status
Date submitted
17/03/2008
Date registered
24/03/2008
Date last updated
18/08/2017

Titles & IDs
Public title
A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Scientific title
A 12-week, Randomised, Double-blind, Placebo-controlled Study to Assess the Anti-inflammatory Activity, Efficacy and Safety of GW856553 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Secondary ID [1] 0 0
MKI102428
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Disease, Chronic Obstructive 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GW856553
Treatment: Drugs - Placebo
Treatment: Drugs - Seretide

Active comparator: Seretide -

Placebo comparator: Placebo - Placebo tablet

Experimental: GW856553 -


Treatment: Drugs: GW856553
Active tablet

Treatment: Drugs: Placebo
Placebo tablet and inhaler

Treatment: Drugs: Seretide
Active comparator inhaler
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline in percentage of neutrophils in induced sputum at Week 12
Timepoint [1] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [1] 0 0
Change from Baseline in Plethysmography measures at Week 12
Timepoint [1] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [2] 0 0
Change from Baseline in pulmonary function assessed by forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) at Week 12
Timepoint [2] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [3] 0 0
Change from Baseline in pulmonary function assessed by FEV1/FVC at Week 12
Timepoint [3] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [4] 0 0
Change from Baseline in pulmonary function assessed by impulse oscillometry [Peripheral airway resistance (R5 - R15)] at Week 12
Timepoint [4] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [5] 0 0
Change from Baseline in pulmonary function assessed by impulse oscillometry: Total resistance (R5) and large airway resistance (R25) of the lung at Week 12
Timepoint [5] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [6] 0 0
Change from Baseline in pulmonary function assessed by impulse oscillometry: Resonant frequency (RF) and X5 as indicators of the reactive capacitance properties of the lung at Week 12
Timepoint [6] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [7] 0 0
Ratio of pulmonary function assessed by impulse oscillometry at Week 12 to Baseline: low-frequency reactance area (AX) as indicator of the reactive capacitance properties of the lung
Timepoint [7] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [8] 0 0
Ratio of plasma fibrinogen assessment at Week 12 to Baseline
Timepoint [8] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [9] 0 0
Ratio of biomarker assessment: Serum Surfactant Protein D (SP-D) and Clara cell protein 16 (CCP-16) at Week 12 to Baseline
Timepoint [9] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [10] 0 0
Ratio of High Sensitivity C-reactive Protein (hsCRP) at Week 12 to Baseline
Timepoint [10] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [11] 0 0
Ratio of biomarker assessment: Interleukin 6 (IL-6), Interleukin 8 (IL-8) Matrix Metallopeptidase 9 (MMP-9) and PARC (Pulmonary and activation-regulated chemokine) at Week 12 to Baseline
Timepoint [11] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [12] 0 0
Ratio of biomarker sorbitol-Induced phosphorylated heat shock protein (pHSP-27) in whole blood pre-dose and 2 h post-dose assessment at Week 12 to Baseline
Timepoint [12] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [13] 0 0
Ratio of biomarker LPS-Induced TNFa Release (pre and post dose) assessment at Week 12 to Baseline
Timepoint [13] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [14] 0 0
Ratio of total leukocyte count in induced sputum assessments at Week 12 to Baseline
Timepoint [14] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [15] 0 0
Change from Baseline in sputum assessment for macrophages as a percentage of total cells at Week 12
Timepoint [15] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [16] 0 0
Change from Baseline in sputum assessment for lymphocytes and eosinophils as a percentage of total cells at Week 12
Timepoint [16] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [17] 0 0
Change from Baseline in sputum assessment for lymphocytes and eosinophils as absolute inflammatory cell numbers at Week 12
Timepoint [17] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [18] 0 0
Ratio of sputum assessment for Neutrophils and macrophages as absolute inflammatory cell numbers at Week 12 to Baseline
Timepoint [18] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [19] 0 0
Ratio of sputum weight and volume at Week 12 to Baseline
Timepoint [19] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [20] 0 0
Ratio of concentration of inflammatory biomarkers (ng/ml)-myeloperoxidase (MPO) at Week 12 to Baseline
Timepoint [20] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [21] 0 0
Ratio of concentration of inflammatory biomarkers (ug/ml)- total protein at Week 12 to Baseline
Timepoint [21] 0 0
Baseline (Week 0) and Week 12

Eligibility
Key inclusion criteria
Subjects eligible for enrolment in the study must meet all of the following criteria:

* Male adults or female adults of non-childbearing potential who are between 40 and 75 years of age (inclusive). Note: a female is eligible to enter and participate in the study if she is of non-childbearing potential (i.e. physiologically incapable of becoming pregnant). This includes any female who is post-menopausal. For the purposes of this study, post menopausal is defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. Postmenopausal status may be confirmed by serum FSH and oestradiol concentrations at screening if deemed necessary by the PI. Surgical sterility will be defined as females who have had a hysterectomy and/or bilateral oophorectomy or tubal ligation.
* Chronic obstructive pulmonary disease diagnosis: an established clinical history of COPD in accordance with the following description by the American Thoracic Society/European Respiratory Society [American Thoracic Society / European Respiratory Society, 2004] Chronic obstructive pulmonary disease is a preventable and treatable disease characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
* Subjects with a cigarette smoking history of =10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year or the equivalent). Both current and former smokers are eligible to be enrolled. A former smoker is defined as a subject who has not smoked for =6 months at Visit 1.
* Subjects with a post-bronchodilator FEV1 to FVC ratio (FEV1:FVC) < 0.7 at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 µg.
* Subjects with a post-bronchodilator FEV1 = 50% and < 80% of predicted normal for height, age and sex at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 µg.
* Subjects capable of providing signed written informed consent to participate.
* Subjects must have a QTc <450 msec on baseline ECG or triplicate ECG averaged over a brief recording interval. For subjects with baseline bundle branch block the QTc will be <480msec on baseline ECG or triplicate ECG averaged over a brief recording interval.
* A subject will be eligible for randomisation at the end of the run-in period only if the following additional criterion applies: Subjects with no evidence of an ongoing acute infection or sinus symptoms Specific information regarding warnings, precautions, contraindications, AEs, and other pertinent information on the investigational product that may impact subject eligibility is provided in the Investigator Brochure/Investigator Brochure supplement(s), product label, and other pertinent documents.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply:

* Women who are pre-menopausal and of child-bearing potential, or pregnant.
* Subjects with a primary diagnosis of asthma or a-1 antitrypsin deficiency.
* Subjects who have required hospitalisation or treatment with oral corticosteroids and/or antibiotic therapy for acute worsening of COPD or lower respiratory tract infection in the 6 weeks prior to Visit 1
* Subjects with active tuberculosis or being treated for active tuberculosis, sarcoidosis or clinically overt bronchiectasis.
* Subjects with a history of any type of malignancy with the exception of successfully treated squamous cell cancer of the skin.
* Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with chronic inflammation (e.g. inflammatory bowel disease).
* Subjects with chronic infections such as gingivitis, periodontitis, prostatitis, gastritis, and urinary tract infections.
* Subjects with any acute infection, sinus symptoms, or significant trauma (burns, fractures).
* Subjects with clinically significant renal disease, diabetes mellitus/metabolic syndrome, hypertension or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy (see Section 6.6.1).
* Subjects with clinically significant gastrointestinal or hepatic abnormalities.
* Subjects with hypoxaemia. (All subjects must have an O2 saturation of = 88% on room air).
* History of Gilbert's syndrome. Subjects with a total bilirubin concentration above the upper limit of normal at Visit 1 will be excluded.
* Liver function tests (bilirubin, ALT, or AST) above upper limit of normal at Visit 1. The subject has a positive Hepatitis B surface antigen or Hepatitis C antibody result within 3 months of the start of the study.The subject has a history of HIV or other immunosuppressive disease.
* Subjects who have undergone recent surgery including lung volume reduction surgery or have conditions that prevent them from performing spirometry.
* Subjects with a history (or suspected history) of alcohol misuse or any other substance abuse.
* The subject has a three month prior history of regular alcohol consumption exceeding an average weekly intake of > 21 units (or an average daily intake of greater than 3 units) for males, or an average weekly intake of > 14 units (or an average daily intake of greater than 2 units) for females. 1 unit is equivalent to a half-pint (284mL) of beer/lager; 25mL measure of spirits or 125mL of wine; or a positive alcohol breath test at the screening visit
* Subjects who will commence or who are likely to commence statin therapy (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) or treatment with intranasal or topical corticosteroids, acetylsalicyclic acid, non-steroidal anti-inflammatory drugs, gemfibrozil, clopidogrel, abciximab, peroxidase proliferator-activated receptor ? agonists (e.g, rosiglitazone), fibrates, or niacin from Visit 1 until study completion. (Subjects who are receiving these medications at a stable dose at Visit 1 may be entered in the study.)
* Subjects who require treatment with any of the following from the Visit 1 until study completion:

* Inhaled corticosteroids
* Inhaled cromolyn sodium or nedocromil
* Xanthines (theophylline preparations)
* Leukotriene modifiers
* Tiotropium
* Long-acting inhaled ß2-agonists (salmeterol, formoterol)
* Oral ß2-agonists
* Macrolide antibiotics for more than five days
* Subjects who have received treatment with oral, intravenous or intra-articular corticosteroids within 6 weeks of Visit 1 or thereafter.
* Subjects with any known hypersensitivity to salbutamol or ipratropium bromide.
* Subjects who are participating or plan to participate in the active phase of a pulmonary rehabilitation programme during the study. Maintenance rehabilitation is permitted.
* Subjects who have received an investigational drug within 30 days or within five drug half-lives of the investigational drug (whichever is longer).
* Subjects with any clinically relevant abnormality detected by the assessments at Visit 1
* An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women; or unwillingness of the male subject to use a condom/spermicide in addition to having their female partner use another form of contraception such as an intra-uterine devices, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation if the woman could become pregnant from the time of the first dose of investigational product for the duration of the study (i.e., through the follow-up phase).
* Subjects who have had a close household contact treated for active tuberculosis within the past 12 months, or who in the judgement of the investigator are at high risk for developing active tuberculosis, shall be excluded from the study.
* A subject will not be eligible for randomisation at the end of the run-in period if either of the following criteria applies:

* Subjects who have experienced an exacerbation during the run-in period requiring treatment with oral corticosteroids and/or antibiotics and/or hospitalisation.
* Subjects who are unable to produce an induced sputum sample.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/02/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/07/2009
Sample size
Target
Accrual to date
Final
306
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Estonia
State/province [1] 0 0
Tallinn
Country [2] 0 0
Estonia
State/province [2] 0 0
Tartu
Country [3] 0 0
Finland
State/province [3] 0 0
Helsinki
Country [4] 0 0
Germany
State/province [4] 0 0
Bayern
Country [5] 0 0
Germany
State/province [5] 0 0
Rheinland-Pfalz
Country [6] 0 0
Germany
State/province [6] 0 0
Sachsen-Anhalt
Country [7] 0 0
Germany
State/province [7] 0 0
Schleswig-Holstein
Country [8] 0 0
Germany
State/province [8] 0 0
Berlin
Country [9] 0 0
Korea, Republic of
State/province [9] 0 0
Seoul
Country [10] 0 0
Latvia
State/province [10] 0 0
Riga
Country [11] 0 0
Lithuania
State/province [11] 0 0
Klaipeda
Country [12] 0 0
Netherlands
State/province [12] 0 0
Breda
Country [13] 0 0
Netherlands
State/province [13] 0 0
Heerlen
Country [14] 0 0
Netherlands
State/province [14] 0 0
Veldhoven
Country [15] 0 0
New Zealand
State/province [15] 0 0
Auckland
Country [16] 0 0
New Zealand
State/province [16] 0 0
Wellington
Country [17] 0 0
Russian Federation
State/province [17] 0 0
Barnaul
Country [18] 0 0
Russian Federation
State/province [18] 0 0
Moscow
Country [19] 0 0
Russian Federation
State/province [19] 0 0
Saint-Petersburg
Country [20] 0 0
Russian Federation
State/province [20] 0 0
St. Petersburg
Country [21] 0 0
Slovenia
State/province [21] 0 0
Kamnik
Country [22] 0 0
Slovenia
State/province [22] 0 0
Ljubljana
Country [23] 0 0
South Africa
State/province [23] 0 0
Gauteng
Country [24] 0 0
South Africa
State/province [24] 0 0
Amanzimtoti
Country [25] 0 0
South Africa
State/province [25] 0 0
Mowbray
Country [26] 0 0
United Kingdom
State/province [26] 0 0
Oxfordshire
Country [27] 0 0
United Kingdom
State/province [27] 0 0
Cottingham, East Yorkshire
Country [28] 0 0
United Kingdom
State/province [28] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Phase IIa, randomised, double-blind, double-dummy, parallel group, multi-centre study in subjects diagnosed with moderate chronic obstructive pulmonary disease (COPD). The primary objective is to evaluate the effects of 12-weeks of treatment with GW856553 7.5 mg twice daily (BID) compared with placebo on the percentage of sputum neutrophils at 12 weeks. Twelve weeks of treatment with SERETIDE 50/500 BID will be compared with placebo for effect on sputum neutrophils as a positive control arm in the study
Trial website
https://clinicaltrials.gov/study/NCT00642148
Trial related presentations / publications
Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R; Losmapimod Study Investigators. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2012 Mar;52(3):416-24. doi: 10.1177/0091270010397050. Epub 2011 Nov 16.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00642148